BTK and non-small cell lung carcinoma: In summary, the anti-tumor progression efficacy combined with the already clinically validated safety profile during clinical testing as a BTK kinase inhibitor makes ibrutinib a potentially useful drug candidate for first line treatment of EGFR primary mutation- driven NSCLC.